Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Four new species of the genus Thorell, 1869 from China are described: Lin & S. Li, (♂♀), Lin & S. Li, (♀), Lin & S. Li, (♀), and Lin & S. Li, (♀). The unknown sexes of Tang & S. Li, 2010 (♂), Li et al., 1985 (♀), Tang & S. Li, 2010 (♂), and Song, 1990 (♀) are described for the first time. Peng, Yin & Kim is treated as a nomen dubium.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837501 | PMC |
| http://dx.doi.org/10.3897/zookeys.1085.77966 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GroEL Accelerates Abdominal Aortic Aneurysm Formation by Induction of M1 Polarization in Macrophages.
Int J Mol Sci
August 2025
Taipei Heart Institute, Taipei Medical University, Taipei 110, Taiwan.
Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease characterized by chronic inflammation, extracellular matrix degradation, and smooth muscle cell apoptosis. (), a key periodontal pathogen, has been implicated in the progression of cardiovascular diseases, including AAA, but the underlying mechanisms remain unclear. In this study, we investigated the role of GroEL, a bacterial heat shock protein 60 homolog derived from , in AAA development.
View Article and Find Full Text PDFCD4/CD8 ratio trajectories and their impact on prognosis: a 15-year retrospective longitudinal cohort study of people living with HIV.
BMC Public Health
August 2025
The Eighth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510440, China.
Introduction: The aim of this study was to identify the heterogeneous classes of CD4/CD8 ratio trajectory and their impacts on prognosis in people living with HIV (PLHIV) during long-term antiretroviral therapy.
Methods: A retrospective cohort study of PLHIV receiving ART treatment was conducted in the Eighth Affiliated Hospital of Guangzhou Medical University, and the latent growth mixture model (LGMM) was used to identify the trajectories of longitudinal changes in the CD4/CD8 ratio between February 10, 2004, and January 31, 2019. Cox proportional hazard model and proportional subdistribution hazard model were conducted to explore the impact of CD4/CD8 ratio trajectory on prognosis.
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.
Eur J Cancer
September 2025
Department of Medical Oncology, Tongji University Shanghai East Hospital, Shanghai, China.
Background: In the phase 3 FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) studies, fruquintinib vs placebo, plus best supportive care, significantly improved overall survival (OS) in patients with metastatic colorectal cancer (mCRC). These studies were conducted in temporally and geographically diverse populations that received distinct prior therapies; FRESCO patients were less pretreated than FRESCO-2 patients. This analysis assessed the efficacy and safety of fruquintinib in a less pretreated global population than the FRESCO-2 intention-to-treat (ITT) population.
View Article and Find Full Text PDFHepatic CBP/p300 Orchestrate Amino Acid-Driven Gluconeogenesis through Histone Crotonylation.
Adv Sci (Weinh)
August 2025
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
The role of amino acid metabolism dysregulation in the development of type 2 diabetes remains elusive. Here, significant associations of human CREBBP/EP300 gene polymorphisms with circulating amino acid and glucose levels are reported. Through integrated transcriptomic, metabolomic, and CUT&Tag analyses, the molecular mechanisms underlying these correlations are investigated.
View Article and Find Full Text PDFTalazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Lancet
August 2025
Institut Gustave Roussy, Centre Oscar Lambret, University of Paris-Saclay, Villejuif, France. Electronic address:
Background: The primary analysis of this phase 3 trial combining talazoparib with enzalutamide demonstrated significantly improved radiographic progression-free survival (rPFS) versus enzalutamide plus placebo in patients with metastatic castration-resistant prostate cancer unselected for homologous recombination repair (HRR) gene alterations. Overall survival data were immature at that time. Here we report the final prespecified overall survival analysis, an updated descriptive analysis of rPFS, and safety in the cohort unselected for HRR gene alterations.
View Article and Find Full Text PDF